Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Lucid Diagnostics (Nasdaq: LUCD) announced that CEO and chairman Lishan Aklog, M.D., will take part in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026 at 10:15 AM EDT.
The event will be webcast live and a replay will be archived on the company's Investor Relations website for 30 days.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – LUCD
On the day this news was published, LUCD gained 2.68%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed moves, with key peer RCEL appearing in momentum scanners and up 4.39%, while others are modestly positive or negative. With LUCD flat on the day, trading appears stock-specific rather than part of a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 02 | Leadership & portfolio | Positive | -0.9% | PAVmed appointed new medical devices leader and licensed Duke imaging tech. |
| Mar 30 | Earnings & financing | Positive | +2.7% | PAVmed reported Q4/FY25 results with financings and business update. |
| Mar 26 | Lucid earnings update | Neutral | -3.4% | Lucid reported Q4/FY25 results, VA contract and EsoGuard performance data. |
| Mar 16 | PAVmed call announcement | Neutral | +4.4% | PAVmed announced timing for Q4/FY25 business update call and webcast. |
| Mar 12 | Lucid call announcement | Neutral | -4.1% | Lucid scheduled Q4/FY25 business update conference call and webcast. |
Recent news, including earnings and conference calls, has often seen price moves in both directions, with one clear divergence where seemingly positive strategic news coincided with a mild decline.
Over the past month, LUCD and parent PAVmed have reported multiple updates, including Lucid’s Q4 and full-year 2025 results on Mar 26 with EsoGuard revenue of $1.5M and full-year revenue of $4.706M, plus a VA contract and strong real-world technical performance. PAVmed issued its own business update and results on Mar 30. Both companies also scheduled and held business update calls in mid-to-late March. Against this backdrop, today’s conference participation fits into an active investor-relations cadence.
Regulatory & Risk Context
An effective S-3/A shelf filed on 2026-03-25 allows Lucid to offer up to $175,000,000 of various securities, including an at-the-market program for up to $25,000,000 of common stock and the inclusion of $50,000,000 of unsold securities from a prior registration. A 424B5 filed on 2026-03-26 reflects initial ATM usage.
Market Pulse Summary
This announcement adds another investor-relations touchpoint, with Lucid’s CEO presenting at the Needham conference on April 16, 2026. It follows Q4/FY25 results, where revenue reached $4.7M and net loss was $58.0M, and recent SEC filings including a $175,000,000 shelf and $25,000,000 ATM program. Investors may watch for any new disclosures or commentary on capital plans, commercialization progress, and how management addresses previously flagged going-concern risks.
AI-generated analysis. Not financial advice.
The fireside chat will be webcast live and available via the Investor Relations Section of the Lucid Diagnostics website or by clicking here. A replay of the webcast will be archived on the website for 30 days following the live event.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-participate-in-fireside-chat-at-the-25th-annual-needham-virtual-healthcare-conference-302736626.html
SOURCE Lucid Diagnostics